Corresponding Author: Albert L. Lin, MD, Department of Ophthalmology, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216 (alin@umc.edu).
Published Online: February 3, 2022. doi:10.1001/jamaophthalmol.2021.4983
Conflict of Interest Disclosures: Dr Lin reported advisory board consulting fees of $1800 from Allergan about dexamethasone intravitreal implant (Ozurdex) outside the submitted work. No other disclosures were reported.
Additional Contributions: We thank the patient for granting permission to publish this information.
1.Agarwal
A. Gass’s Atlas of Macular Diseases. 5th ed. Saunders; 2012 274-280.
4.Giuffrè
C , Miserocchi
E , Modorati
G ,
et al. Central serous chorioretinopathy-like mimicking multifocal vitelliform macular dystrophy: an ocular side effect of mitogen/extracellular signal-regulated kinase inhibitors.
Retin Cases Brief Rep. 2018;12(3):172-176. doi:
10.1097/ICB.0000000000000491PubMedGoogle ScholarCrossref 5.Sandhu
HS , Kolomeyer
AM , Lau
MK ,
et al. Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vemurafenib and pembrolizumab treatment for metastatic melanoma.
Retin Cases Brief Rep. 2019;13(2):103-107. doi:
10.1097/ICB.0000000000000604PubMedGoogle ScholarCrossref 8.Querques
G , Zerbib
J , Santacroce
R ,
et al. The spectrum of subclinical Best vitelliform macular dystrophy in subjects with mutations in
BEST1 gene.
Invest Ophthalmol Vis Sci. 2011;52(7):4678-4684. doi:
10.1167/iovs.10-6500PubMedGoogle ScholarCrossref